ClinicalTrials.gg
CompletedNCT01373450Updated Sep 2, 2015Results posted

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

A Phase 1 interventional study of Oxyntomodulin and Liraglutide 0.6 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2015-09-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
139th of 151
12 · median 62
Started
2011
with 10 others
Phase 1
25 of 151
none open now
Registered
28th of 151
by date

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 139th largest by enrollment, is one of 11 that started in 2011, is one of 25 in phase 1, and was the 28th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 64 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM). Participants were randomly assigned to 1 of 6 treatment sequences consisting of 4 treatment periods, with a 7-day wash-out between each treatment period. The primary hypothesis was that during graded glucose infusion (GGI) oxyntomodulin (OXM) is neutral or better than placebo (Pbo) at lowering ambient plasma glucose levels, and at significantly enhancing insulin secretion.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of ≤38.0 kg/m\^2
  • Have a clinical diagnosis of Type 2 diabetes mellitus
  • Have a (HbA1C) at screening ≤9.0%; fasting plasma glucose should not exceed 300 mg/dL (16.8 mmol/L)
  • Judged to be in good health

Exclusion criteria

Exclusion Criteria:

  • Have a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study
  • Have a history of stroke, chronic seizures, major neurological disorder, endocrine, cardiovascular, hematological, hepatic, renal, respiratory, or genitourinary abnormalities or diseases
  • Have untreated hypertension with blood pressure of >160/95 mmHg
  • Have a history of neoplastic disease within the past 5 years
  • Have a history of to OXM, liraglutide, insulin or Haemaccel®
  • Unable or unwilling to comply with restrictions around concomitant medications
  • Consume excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages daily
  • Have had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another study within 4 weeks
  • Have a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
  • Currently a regular user (including use of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 months
  • Are unwilling or unable to consume the standardized meals during the study and/or is on a carbohydrate restricted diet (i.e., a diet \<100 grams per day of carbohydrate)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    OXM → Lg-0.6 → Pbo → Lg-1.2

    Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

  • Experimental
    Lg-0.6 → Pbo → OXM → Pbo

    Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

  • Experimental
    Pbo → OXM → Lg-0.6 → Pbo

    Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

  • Experimental
    Lg-0.6 → OXM → Pbo → Lg-1.2

    Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Liraglutide 1.2 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

  • Experimental
    OXM → Pbo → Lg-0.6 → Pbo

    Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

  • Experimental
    Pbo → Lg-0.6 → OXM → Lg-1.2

    Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period

    Drug: Oxyntomodulin · Drug: Liraglutide 0.6 mg · Drug: Liraglutide 1.2 mg · Drug: Placebo for Oxyntomodulin · Drug: Placebo for Liraglutide

Interventions

  • DrugOxyntomodulin

    3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

  • DrugLiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single subcutaneous dose in the evening of the day before the GGI (Day-1)

    Also known as: Victoza®

  • DrugLiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single subcutaneous dose in the evening of the day before the GGI (Day-1)

    Also known as: Victoza®

  • DrugPlacebo for Oxyntomodulin

    IV infusion in the morning of the day of GGI (Day 1)

  • DrugPlacebo for Liraglutide

    Single subcutaneous dose in the evening of the day before the GGI (Day-1)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)

    Participants received on Day (-1) an overnight intravenous (IV) infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of liraglutide (Lg) or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of graded glucose infusion (GGI). During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI at the following minutes: 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 in order to calculate the time-weighted average change from baseline in glucose AUC from 0-160 minutes.

    Time frame: Baseline and during GGI at time points 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 minutes

  2. Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM

    Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.

    Time frame: Baseline and up to 160 minutes after start of GGI

  3. Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM

    Beta cell sensitivity measures the ability to mount an insulin secretory response relative to the level of ambient plasma glucose. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI, with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR). Beta Cell Sensitivity (Φ) was determined from the regression of the ISR on ambient plasma glucose (G).

    Time frame: Baseline and up to160 minutes after start of GGI

Secondary outcomes

  1. Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment

    The reproducibility of insulinotrophic effects was compared after two separate placebo treatment periods within the same treatment sequence. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single subcutaneous dose of placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Over these two treatment periods glucose (G), insulin and C-peptide levels were measured from blood collected at the highest glucose infusion rate; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR), and hence to determine the insulinotrophic effect, ISR/G.

    Time frame: Baseline and 160 minutes after start of GGI at each placebo treatment period

  2. Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM

    Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.

    Time frame: Baseline and up to 160 minutes after start of GGI

  3. Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM

    Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR) and hence determine ISR/G.

    Time frame: Baseline and up to 160 minutes after start of GGI

07

Results

Posted Jul 8, 2013

Participant flow

Crossover Period 1
Participant flow — Crossover Period 1
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
7 Day Wash-out
Participant flow — 7 Day Wash-out
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
Crossover Period 2
Participant flow — Crossover Period 2
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
7 Day Wash-out
Participant flow — 7 Day Wash-out
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
Crossover Period 3
Participant flow — Crossover Period 3
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
7 Day Wash-out
Participant flow — 7 Day Wash-out
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000
Crossover Period 4
Participant flow — Crossover Period 4
MilestoneOXM --> Lg-0.6--> Pbo--> Lg-1.2Lg-0.6 mg--> Pbo--> OXM--> PboPbo--> OXM--> Lg-0.6-->PboLg-0.6--> OXM--> Pbo--> Lg-1.2OXM--> Pbo--> Lg-0.6--> PboPbo--> Lg-0.6--> OXM--> Lg-1.2
Started222222
Completed222222
Not completed000000

Outcome measures

PrimaryChange From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)

Participants received on Day (-1) an overnight intravenous (IV) infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of liraglutide (Lg) or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of graded glucose infusion (GGI). During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI at the following minutes: 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 in order to calculate the time-weighted average change from baseline in glucose AUC from 0-160 minutes.

Time frame:
Baseline and during GGI at time points 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 minutes
Reported as:
Least squares mean · mg/dL
Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)
mg/dLOxyntomodulinPlacebo
Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)106.3 ± 23.03122.6 ± 35.29
Statistical analysis
  • Oxyntomodulin vs Placebo · t-test, 1 sided · p = 0.024 · Geometric mean ratio: 0.87 · 90% CI 0.77 to 0.98
PrimaryChange From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM

Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.

Time frame:
Baseline and up to 160 minutes after start of GGI
Reported as:
Least squares mean · mg/dL
Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM
mg/dLOxyntomodulinPlacebo
Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM211.0 ± 63.00272.9 ± 50.05
Statistical analysis
  • Oxyntomodulin vs Placebo · t-test, 1 sided · p = 0.004 · Geometric mean ratio: 0.77 · 90% CI 0.66 to 0.90
PrimaryChange From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM

Beta cell sensitivity measures the ability to mount an insulin secretory response relative to the level of ambient plasma glucose. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI, with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR). Beta Cell Sensitivity (Φ) was determined from the regression of the ISR on ambient plasma glucose (G).

Time frame:
Baseline and up to160 minutes after start of GGI
Reported as:
Least squares mean · ISR (ng/mL) / Glucose (mg/dL)
Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM
ISR (ng/mL) / Glucose (mg/dL)OxyntomodulinPlacebo
Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM0.019 ± 0.0100.006 ± 0.003
Statistical analysis
  • Oxyntomodulin vs Placebo · t-test, 1 sided · p = <0.001 · Least square mean difference: 0.014 · 90% CI 0.008 to 0.019
SecondaryChange From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment

The reproducibility of insulinotrophic effects was compared after two separate placebo treatment periods within the same treatment sequence. Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single subcutaneous dose of placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Over these two treatment periods glucose (G), insulin and C-peptide levels were measured from blood collected at the highest glucose infusion rate; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR), and hence to determine the insulinotrophic effect, ISR/G.

Time frame:
Baseline and 160 minutes after start of GGI at each placebo treatment period
Reported as:
Mean · ISR (ng/mg) / Glucose (mg/dL)
Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment
ISR (ng/mg) / Glucose (mg/dL)Placebo Period 1Placebo Period 2
Change From Baseline in Insulinotrophic Effect (ISR/G) at the Highest Glucose Infusion Rate After Two Periods of Placebo Treatment0.0075 ± 0.00310.0070 ± 0.0027
Statistical analysis
  • Placebo Period 1 vs Placebo Period 2 · Intraclass correlation coefficient: 0.92 · 90% CI 0.72 to 0.98
SecondaryChange From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM

Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose levels were measured from blood collected at baseline and during GGI to determine the maximum ambient glucose concentration above baseline.

Time frame:
Baseline and up to 160 minutes after start of GGI
Reported as:
Least squares mean · mg/dL
Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM
mg/dLLiraglutide 0.6 mgLiraglutide 1.2 mgOxyntomodulinPlacebo
Change From Baseline in Gmax After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM209.7 ± 66.08157.9 ± 93.36211.0 ± 63.00272.9 ± 50.05
Statistical analysis
  • Liraglutide 0.6 mg vs Placebo · t-test, 1 sided · p = 0.003 · Geometric mean ratio: 0.77 · 90% CI 0.66 to 0.90
  • Liraglutide 1.2 mg vs Placebo · t-test, 1 sided · p = <0.001 · Geometric mean ratio: 0.58 · 90% CI 0.45 to 0.74
  • Liraglutide 0.6 mg vs Oxyntomodulin · t-test, 1 sided · p = 0.473 · Geometric mean ratio: 0.99 · 90% CI 0.85 to 1.16
  • Liraglutide 1.2 mg vs Oxyntomodulin · t-test, 1 sided · p = 0.049 · Geometric mean ratio: 0.75 · 90% CI 0.56 to 1.00
SecondaryChange From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM

Participants received on Day (-1) an overnight IV infusion of insulin titrated to achieve baseline fasting plasma glucose on Day 1 of between 90 and 130 mg/dL. Participants also received on Day (-1) a single dose of Lg or placebo for Lg, after which insulin infusion was discontinued. Following overnight fast, participants received on Day 1 a single dose of OXM or placebo for OXM, accompanied by up to 160 minutes of GGI. During GGI glucose (20% D/W) was gradually infused at rates of 2,4,6 and 10 mg/kg/min, with each rate lasting approximately 40 minutes. Glucose (G), insulin and C-peptide levels were measured from blood collected at baseline and during GGI; with the decay in C-peptide concentration used to indirectly estimate the Insulin Secretion Rate (ISR) and hence determine ISR/G.

Time frame:
Baseline and up to 160 minutes after start of GGI
Reported as:
Least squares mean · ISR (ng/min) / Glucose (mg/dL)
Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM
ISR (ng/min) / Glucose (mg/dL)Liraglutide 0.6 mgLiraglutide 1.2 mgOxyntomodulinPlacebo
Change From Baseline in Insulinotrophic Effect (ISR/G) After Single Doses of 0.6 mg Lg, or 1.2 mg Lg, Compared With Single Doses of Placebo or OXM0.026 ± 0.0150.035 ± 0.0180.019 ± 0.0100.006 ± 0.003
Statistical analysis
  • Liraglutide 0.6 mg vs Placebo · t-test, 1 sided · p = <0.001 · Least square mean difference: 0.021 · 90% CI 0.015 to 0.026
  • Liraglutide 1.2 mg vs Placebo · t-test, 1 sided · p = <0.001 · Least square mean difference: 0.030 · 90% CI 0.021 to 0.038
  • Liraglutide 0.6 mg vs Oxyntomodulin · t-test, 1 sided · p = 0.0163 · Least square mean difference: 0.007 · 90% CI 0.002 to 0.012
  • Liraglutide 1.2 mg vs Oxyntomodulin · t-test, 1 sided · p = 0.0056 · Least square mean difference: 0.016 · 90% CI 0.006 to 0.026

Adverse events

Collected over Up to 14 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxyntomodulin—0/12 (0%)6/12 (50%)
Liraglutide 0.6 mg—0/12 (0%)7/12 (58.3%)
Liraglutide 1.2 mg—0/6 (0%)1/6 (16.7%)
Placebo—0/12 (0%)8/12 (66.7%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOxyntomodulinLiraglutide 0.6 mgLiraglutide 1.2 mgPlacebo
HeadacheNervous system disorders2/124/120/63/12
FatigueGeneral disorders2/123/120/61/12
Catheter Site PainGeneral disorders0/120/121/61/12
Catheter Site Related ReactionGeneral disorders1/120/120/62/12
Dry MouthGastrointestinal disorders0/121/120/61/12
NauseaGastrointestinal disorders0/120/120/61/12
Salivary HypersecretionGastrointestinal disorders0/120/120/61/12
Oedema PeripheralGeneral disorders1/120/120/60/12
RhinitisInfections and infestations1/120/120/60/12
ArthralgiaMusculoskeletal and connective tissue disorders0/120/120/61/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Treated Participants
Mean58.8 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)All Treated Participants
Female0
Male12
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O'Dowd AK, Williams DM, Frederick CB, Beals CR, Stoch SA, Steinberg HO, Kelley DE. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. Diabetes. 2018 Jun;67(6):1105-1112. doi: 10.2337/db17-1331. Epub 2018 Mar 15. PubMed 29545266 ↗
  • Shankar SS, Shankar RR, Mixson LA, Miller DL, Chung C, Cilissen C, Beals CR, Stoch SA, Steinberg HO, Kelley DE. Linearity of beta-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E865-73. doi: 10.1152/ajpendo.00527.2015. Epub 2016 Apr 12. PubMed 27072496 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2011
First posted
Jun 15, 2011
Start
Jun 2011
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Jul 8, 2013
Last update
Sep 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01373450
Responsible party
Sponsor
First posted
Jun 15, 2011
Start date
Jun 2011
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jul 8, 2013
Last update
Sep 2, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion